OnKure Therapeutics
Health Care · Medical AI
Facts
as of Nov 21, 2026OnKure Therapeutics - Writing the Next Chapter in Precision Medicines.
- Legal name
- OnKure Therapeutics, Inc.
- Headquarters
- Boulder, United States
- Employees
- 51-200estimated range
- Legal entities
- 2 in 1 country
- Listing
- NASDAQ: OKUR
- Official records
- Wikidata Q123420969
- Website
- onkuretherapeutics.com
These are the key facts about OnKure Therapeutics on Alion as of Nov 21, 2026. OnKure Therapeutics is headquartered in Boulder, United States. It has raised $282.6M in 14 funding rounds. The latest round is Venture - Series Unknown of $65M, announced in 2024.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 14 records →OnKure Therapeutics has $282.6M paid in by investors, lenders and donors.
$282.6MPaid in
Money innewest first
$65MPaid
$53.8MPaid
$56.6MPaid
11 more records: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Ownership
All holders and entities →OnKure Therapeutics operates through 2 legal entities in 1 country.
Legal entities2 in 1 country
OnKure Therapeutics, Inc.
operator
US
OnKure, Inc.
operator
US
Holders and shares as each register or filing states them.
Products
Products →OnKure Therapeutics has 3 clinical trials on record, 1 under way.
Clinical trials
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
phase 1 · under way · 200 participants · Advanced Cancer; Breast Cancer; Advanced Solid Tumors; PI3K Gene Mutation
Feb 2024
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutate…
phase 2 · completed · 36 participants · RAS Mutation; NRAS Gene Mutation; Melanoma
May 2022
A Study of OKI-179 in Patients With Solid Tumors
phase 1 · completed · 34 participants · Advanced Solid Tumors
May 2019
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →OnKure Therapeutics in public registers.
Legal entity active
OnKure Therapeutics, Inc.
Not checked
No match
None
None
Patents
9
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Boulder United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Milestones
Nov 2026
Went public NASDAQ: OKUR
Oct 4, 2024
Raised a round Venture round $65M · SEC Form D
Apr 3, 2023
Mar 24, 2023
Raised a round Venture round $53.8M · SEC Form D
Each milestone is dated by its source: registers, filings, the press
